Osteoporosis in men: a review

被引:80
作者
Adler, Robert A. [1 ,2 ]
机构
[1] McGuire Vet Affairs Med Ctr, Endocrinol Sect, Richmond, VA 23224 USA
[2] Virginia Commonwealth Univ, Div Endocrine, Sch Med, Richmond, VA USA
来源
BONE RESEARCH | 2014年 / 2卷
关键词
BONE-MINERAL DENSITY; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; ANDROGEN-DEPRIVATION THERAPY; FRACTURE RISK; DOUBLE-BLIND; ZOLEDRONIC ACID; OLDER MEN; SECONDARY OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; LIFETIME RISK;
D O I
10.1038/boneres.2014.1
中图分类号
Q813 [细胞工程];
学科分类号
100113 [医学细胞生物学];
摘要
Osteoporosis and consequent fracture are not limited to postmenopausal women. There is increasing attention being paid to osteoporosis in older men. Men suffer osteoporotic fractures about 10 years later in life than women, but life expectancy is increasing faster in men than women. Thus, men are living long enough to fracture, and when they do the consequences are greater than in women, with men having about twice the 1-year fatality rate after hip fracture, compared to women. Men at high risk for fracture include those men who have already had a fragility fracture, men on oral glucocorticoids or those men being treated for prostate cancer with androgen deprivation therapy. Beyond these high risk men, there are many other risk factors and secondary causes of osteoporosis in men. Evaluation includes careful history and physical examination to reveal potential secondary causes, including many medications, a short list of laboratory tests, and bone mineral density testing by dual energy X-ray absorptiometry (DXA) of spine and hip. Recently, international organizations have advocated a single normative database for interpreting DXA testing in men and women. The consequences of this change need to be determined. There are several choices of therapy for osteoporosis in men, with most fracture reduction estimation based on studies in women.
引用
收藏
页数:8
相关论文
共 79 条
[1]
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate [J].
Abrahamsen, B. ;
Grove, E. L. ;
Vestergaard, P. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (02) :757-762
[2]
Adler R., 2012, FED PRACT, V29, P31
[3]
Adler RA, 2011, J ENDOCRINOL INVEST, V34, P481, DOI [10.1007/BF03346716, 10.3275/7753]
[4]
Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™ [J].
Adler, R. A. ;
Hastings, F. W. ;
Petkov, V. I. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (04) :647-653
[5]
Laboratory testing for secondary osteoporosis evaluation [J].
Adler, Robert A. .
CLINICAL BIOCHEMISTRY, 2012, 45 (12) :894-900
[6]
Secondary Fracture Prevention [J].
Adler, Robert A. .
CURRENT OSTEOPOROSIS REPORTS, 2012, 10 (01) :22-27
[7]
Management of osteoporosis in men on androgen deprivation therapy [J].
Adler, Robert A. .
MATURITAS, 2011, 68 (02) :143-147
[8]
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone [J].
Amory, JK ;
Watts, NB ;
Easley, KA ;
Sutton, PR ;
Anawalt, BD ;
Matsumoto, AM ;
Bremner, WJ ;
Tenover, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :503-510
[9]
Arias E, 2018, US LIFE TABLES, DOI DOI 10.1056/NEJMP1703787
[10]
Risk-adjusted mortality rates of elderly veterans with hip fractures [J].
Bass, Elizabeth ;
French, Dustin D. ;
Bradham, Douglas D. ;
Rubenstein, Laurence Z. .
ANNALS OF EPIDEMIOLOGY, 2007, 17 (07) :514-519